内野 慶太 うちの けいた 先生

来歴等

略歴

2002年 香川医科大学医学部 卒業
2009年 九州大学病院
2011年 九州医療センター
2018年 NTT東日本関東病院

論文

• Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines. Anticancer Drugs 20 (2): 123-130, 2009

  Makiyama A, Qin B, Uchino K, Shibata Y, Arita S, Isobe T, Hirano G,Kusaba H, Baba E, Akashi K, Nakano S

• Validation of Hospital Anxiety and Depression Scale as a screening tool for psychological distress in advanced cancer patients undergoing chemotherapy. Palliative Care Res 6 (2): 150-157, 2011

  Uchino K, Kusaba H, Kishimoto J, Mitsuyasu H, Kawasaki H, Baba E, Akashi K

• Phase 2 Study of Modified Irinotecan and Bolus 5-Fluorouracil/l-Leucovorin in Japanese Metastatic Colorectal Cancer Patients. Adv Ther 29 (3): 287-296, 2012

  Baba E, Fujishima H, Makiyama A, Uchino K, Tanaka R, Esaki T, Kusaba H, Mitsugi K, Nakano S, Akashi K

• Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells. Exp Cell Res 318 (15): 1799-1807, 2012

  Uchino K, Hirano G, Hirahashi M, Isobe T, Shirakawa T, Kusaba H, Baba E,Tsuneyoshi M, Akashi K

• Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan. Anticancer Res 35 (1): 371-377, 2015

  Hirano G, Makiyama A, Makiyama C, Esaki T, Oda H, Uchino K, Komoda M, Tanaka R, Matsushita Y, Mitsugi K, Shibata Y, Kumagai H, Arita S, Ariyama H, Kusaba H, Akashi K, Baba E

• A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin. Eur J Cancer Care (Engl) 24 (1): 111-116, 2015

  Yamauchi H, Goto T, Takayoshi K, Sagara K, Uoi M, Kawanabe C, Matsunaga M, Miyoshi T, Uchino K, Misumi N, Nishino T

• Safety and tolerability of vandetanib ㏌ Japanese patients with medullary thyroid cancer: a phase I/II open-label study. Endocr Pract 23 (2): 149-156, 2017

  Uchino K, Komoda M, Tomomatsu J, Okamoto T, Horiuchi K, Tsuji A, Ito Y, Todo T, Rito K, Takahashi S

• Weight Loss During Initial Chemotherapy Predicts Survival in Patients With Advanced Gastric Cancer. Nutr Cancer 69 (3): 408-415, 2017

  Takayoshi K, Uchino K, Nakano M, Ikejiri K, Baba E

• Predictive value of the modified Glasgow Prognostic Score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma. Molecular and clinical oncology 6: 669-675, 2017

  Ohmura H, Uchino K, Kajitani T, Sakamoto N, Baba E

• Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer. Anticancer Res 37: 2663-2671, 2017

  Inadomi K, Kusaba H, Matsushita Y, Tanaka R, Mitsugi K, Arimizu K, Hirano G, Makiyama A, Ohmura H, Uchino K, Hanamura F, Shibata Y, Kuwayama M, Esaki T, Takayoshi K, Arita S, Ariyama H, Akashi K, Baba E

• Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).Gastric Cancer 21: 84-95, 2018

  Miura Y, Sukawa Y, Hironaka S, Mori M, Nishikawa K, Tokunaga S, Okuda H, Sakamoto T, Taku K, Nishikawa K, Moriwaki T, Negoro Y, Kimura Y, Uchino K, Shinozaki K, Shinozaki H, Musha N, Yoshiyama H, Tsuda T, Miyata Y, Sugimoto N, Shirakawa T, Ito M, Yonesaka K, Yoshimura K, Boku N, Nosho K, Takano T, Hyodo I

• The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer.Cancer Chemotherapy and Pharmacology 82: 625-633, 2018

  Yamaguchi K, Kusaba H, Makiyama A, Mitsugi K, Uchino K, Tamura S, Shibata Y, Esaki T, Ito M, Takayoshi K, Tsuchihashi K, Arita S, Ariyama H, Akashi K, Baba E